Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation.
Lindstrom
Richard
R
Holland
Edward
E
Lane
Stephen
S
Raizman
Michael
M
Reilly
Charles
C
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D044482:Benzeneacetamides / Q000008:administration & dosage* / Q000009:adverse effects; D003315:Cornea / Q000601:surgery*; D003318:Corneal Opacity / Q000139:chemically induced; D004311:Double-Blind Method; D006801:Humans; D006956:Hyperopia / Q000601:surgery; D020731:Keratomileusis, Laser In Situ; D020911:Ketorolac Tromethamine / Q000008:administration & dosage* / Q000009:adverse effects; D009216:Myopia / Q000601:surgery; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000009:adverse effects; D010147:Pain Measurement; D010149:Postoperative Pain / Q000188:drug therapy*; D010648:Phenylacetates / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D014792:Visual Acuity / Q000187:drug effects; D014945:Wound Healing / Q000187:drug effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D044482:Benzeneacetamides; D009883:Ophthalmic Solutions; D010648:Phenylacetates; C414203:nepafenac; D020911:Ketorolac Tromethamine